Joint MSU/UofM IP acquired by OncoArendi Therapeutics

 

OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

March 11, 2022

– Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases

– Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF)

 

11 March  2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate RNA and unexplored protein targets to treat multiple incurable diseases, announces it has entered into an option-to-license agreement with Innovation Partnerships at the University of Michigan (U-M)  to develop novel small molecule inhibitors of an undisclosed target, for the treatment of fibrotic diseases.  The novel inhibitors were generated and initially validated as a result of a long-standing research collaboration with Michigan State University (MSU).  U-M entered in the option-to-license agreement with OncoArendi on behalf of both U-M and MSU.

For more information:  https://oncoarendi.com/en/oncoarendi-therapeutics-announces-a-license-option-agreement-with-university-of-michigan/